Pressmeddelande

HC Andersen Capital: Release of new Ascelia Pharma investment case

Cision Publicerad: 31 Mar 2022 09:30

HC Andersen Capital releases new Ascelia Pharma investment case.

Ascelia Pharma’s Phase 3 pipeline product, Orviglance, addresses an unmet need in a market estimated to be USD 500-600m annually. Being a diagnostic product and supported by strong Phase 2 data, there is a solid foundation for obtaining market approval after Phase 3 (completion expected in 2022). The market, however, currently assesses a lower than 25 pct. chance it happens. This implies a large potential if approved.

Read HC Andersen Capital's investment case here.

This is a press release from HC ANDERSEN CAPITAL, https://hcandersencapital.dk.

Bifogade filer

Ascelia-Pharma-Investment-Case-24-March-2022https://mb.cision.com/Main/16300/3536551/1557010.pdf

Nyheter om Ascelia Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!